We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Metastasis-Promoting Gene Identified

By Biotechdaily staff writers
Posted on 12 Mar 2003
Researchers studying how cancer cells metastasize have found that the cyclin D1 gene regulates changes in the morphology of tumor-associated macrophages that enhance their ability to migrate. More...
Their findings were published February 21, 2003, in the online edition of Molecular Biology of the Cell.

Investigators from Georgetown University's Lombardi Cancer Center (Washington, DC, USA) genetically engineered a line of mice lacking the cyclin D1 gene, which encodes the regulatory subunit of a holoenzyme that phosphorylates and inactivates the retinoblastoma protein, pRB, thereby promoting cell-cycle progression. Cyclin D1 is overexpressed in hematopoetic and epithelial malignancies, correlating with poor prognosis and metastasis in several cancer types.

Tumor-associated macrophages from mice lacking the cyclin D1 gene differed in morphology, being rounder and having fewer membrane ruffles than the macrophages from control animals. Migration of these macrophages in response to wounding, cytokine-mediated chemotaxis and transendothelial cell migration were all substantially reduced.

"Patients who do not survive their cancer often do not die from their primary cancer. Usually they die from the spread of the disease through the body. If we can understand what causes the metastasis, then we can pinpoint new targets to block the spread of disease,” said senior author Dr. Richard G. Pestell, director of the Lombardi Cancer Center. "Since cancerous cells migrate, therapy targeted to cell migration would be more selective. Killing only migrating cancer cells is thus less toxic, producing fewer side effects than current chemotherapy, which targets dividing cells of all types.”



Related Links:
Georgetown University Medical Center

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Immunofluorescence Analyzer
IFA System
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.